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Equity in HTA: what doesn’t get measured,
gets marginalised
Richard Cookson* and Andrew J. Mirelman
Abstract
When making recommendations about the public funding of new health technologies, policy makers typically pay
close attention to quantitative evidence about the comparative effectiveness, cost effectiveness and budget impact of
those technologies – what we might call “efficiency” criteria. Less attention is paid, however, to quantitative evidence
about who gains and who loses from these public expenditure decisions, and whether those who gain are better or
worse off than the rest of the population in terms of their health – what we might call “equity” criteria. Two studies
recently published in this journal by Shmueli and colleagues suggest that this efficiency-oriented imbalance in the use
of quantitative evidence may have unfortunate consequences – as the old adage goes: “what gets measured, gets
done”. The first study, by Shmueli, Golan, Paolucci and Mentzakis, found that health policy makers in Israel think equity
considerations are just as important as efficiency considerations – at least when it comes to making hypothetical
technology funding decisions in a survey. By contrast, the second study – by Shmueli alone – found that efficiency
rules the roost when it comes to making real decisions about health technology funding in Israel. Both studies have
limitations and potential biases, and more research is needed using qualitative methods and more nuanced survey
designs to determine precisely which kinds of equity consideration decision makers think are most important and why
these considerations do not appear to be given much weight in decision making. However, the basic overall finding
from the two studies seems plausible and important. It suggests that health technology funding bodies need to pay
closer attention to equity considerations, and to start making equity a quantitative endpoint of health technology
assessment using the methods of equity-informative economic evaluation that are now available.
Across the world, public decision makers responsible for
the funding of new health technologies pay close atten-
tion to quantitative evidence on the comparative effect-
iveness, cost effectiveness and budget impact of those
technologies [1]. Loosely speaking, we can think of this
as evidence about “efficiency”, or getting the biggest sum
total health benefit out of scarce resources. However, re-
searchers and policymakers are increasingly interested in
finding ways of producing quantitative evidence about
broader outcomes relating to “equity”, or fairness in the
distribution of health and health care [2–4]. Two studies
recently published in this journal by Shmueli and col-
leagues [5, 6] show why the quantification of equity out-
comes is so important, by confirming the old adage:
“What gets measured, gets done.” Cost-effectiveness is
measured in health technology assessment (HTA),
whereas equity is not. It is perhaps not surprising to
find, then, that HTA decision-making in Israel is
predominantly driven by cost-effectiveness rather than
equity [6].
The first study examined the views of senior Israeli
health policy makers about the relative importance of
three efficiency and four equity criteria [5]. Policy
makers were asked to make a series of hypothetical
funding choices, in a discrete choice experiment survey
designed in a similar way to a previous multi-national
study led by one of the authors of this commentary [7].
The study found that Israeli policy makers seem to care
at least as much about equity as efficiency – and even
more so than policy makers elsewhere in the world.
According to a regression analysis of the determinants
of their hypothetical choices [5], people directly involved
in health technology funding decisions gave roughly
equal importance to equity and efficiency criteria (a total
estimated weight of 49% for the four equity criteria and
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51% for the three efficiency criteria), and other policy
makers gave slightly higher weight to equity (56%).
The second study examined the relative importance of
these same equity and efficiency criteria as revealed by
actual decisions about the public funding of health tech-
nologies in Israel [6]. It found that efficiency ruled the
roost in practice [6]. The ranking predicted by one effi-
ciency criterion alone – cost-effectiveness in terms of
cost per Quality Adjusted Life Year (QALY) – was rea-
sonably well correlated with the actual ranking (correl-
ation coefficient 0.45). By contrast, the ranking predicted
by the findings of the first study (i.e. using data on how
each technology performs on all four equity criteria and
all three efficiency criteria, weighted by their estimated
importance) was actually negatively correlated with the
actual rankings. In other words, if we take these findings
at face value, decision makers seemed in practice more
likely to choose less equitable technologies!
This glaring discrepancy is particularly interesting be-
cause Shmueli and colleagues were able to elicit views
from 11 former members of the “Basket Committee”,
which makes health technology reimbursement decisions
in Israel, including four former chairs of this committee.
Their sample also included 54 other health policy makers
including past and present senior managers from the
Ministry of Health, Ministry of Finance, sickness funds,
Israeli Medical Association, and hospital directors.
What should we make of these findings? The first
question to ask is whether the findings are credible.
There are certainly many potential sources of bias and
error one could point to in both studies. Quick re-
sponses to hypothetical questions in an on-line survey
may elicit unreflective “socially desirable” responses –
the easy response being that everything matters and all
considerations should be equally well considered. By
contrast, real decisions may concentrate minds on what
matters most under conditions of scarce resources. Also,
the concepts of efficiency and equity are hotly contest-
able, and one can raise all sorts of issues about the selec-
tion and definition of the seven criteria in the study.
The seven binary criteria shown in the table were used,
with the four criteria on the left falling under equity and
the three criteria on the right falling under efficiency.
There is some logical overlap between the second and
third criteria (since a technology for children cannot also
be one for the elderly), between the fourth and fifth
criteria (since the cost of treatment is related to both
cost-effectiveness and whether the poor could otherwise
afford to pay privately), and between the fifth and
seventh criteria (since cost per unit of benefit is a func-
tion of benefit). This co-linearity could potentially bias
the regression estimates of the relative importance of
each criterion. Furthermore, the third and fourth equity
criteria are both ambiguous. Age is partly an efficiency
issue rather than an equity issue, insofar as older
patients may stand to gain fewer years of healthy life,
and it is not clear whether treating the elderly is sup-
posed to be more or less equitable than treating the
middle aged. It is also not clear whether the fourth
equity criterion relates to the effectiveness of the alterna-
tive publicly funded standard of care or the cost of treat-
ment or both; nor is it clear what general equity
objective is being invoked – the objective of reducing
unfair inequality in financial risk protection, of reducing
unfair inequality in the utilisation of care, of reducing
unfair inequality in health outcomes, or something else.
Another issue is the relatively small sample of 34 tech-
nologies used in the second study, which may not be
enough to draw robust inferences about which factors
drive decision-making. A previous study in England had
a much larger sample and used a regression approach to
analyse the determinants of decision acceptance [8].
Interestingly, however, that study similarly found that
cost-effectiveness was the dominant criteria for decision-
making in England.
One might also worry about various kinds of selection
bias. While the number of Israeli policy makers who
responded to the survey is impressive (65 out of 147
contacted), it is not clear how representative they are of
health policy makers more generally in Israel. The deci-
sions selected in study two all relate to the year 2006/7,
while the survey was conducted nearly a decade later.
We are told that it was a random sample of 18 accepted
and 16 rejected technologies in 2006/7, though no de-
tails are given of the randomisation process or the total
number of decisions in the full population. More im-
portantly, there is potential for bias in the selection of
reported point estimates for the seven decision criteria.
In our experience of retrospectively analysing decisions
by the National Institute for Health and Clinical
Equity criteria Efficiency criteria
1. The technology is intended for patients suffering from a serious
disease (life expectancy is less than 2 healthy years).
5. Cost per Quality Adjusted Life Year: Less than the GNP
[Gross National Product] per capita.
2. The technology is intended to treat a disease common among
children.
6. The Number of patients requiring the technology: more than
100,000.
3. The technology is intended to treat a disease common among
the elderly.
7. Individual Benefit: addition of more than 5 healthy years.
4. Funding the technology is required so that the poor can use it.
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Excellence (NICE) in England, reporting of information is
patchy and ambiguous. Hence many technology appraisal
decisions cannot be included in studies of this kind, or re-
quire the analyst to make questionable assumptions about
which of many different reported estimate to use. So it
would be a sign of exemplary transparency on the part of
the Israeli authorities – far better than in England – if
enough clear and precise published details were provided
on every single technology, not only to include in the ran-
dom sample, but also to provide unambiguous point esti-
mates on each of the seven decision criteria.
Despite these concerns, it is reasonable to conclude
that the study does tell us something useful about the
relative importance of equity and efficiency consider-
ations in the minds of decision makers. More research is
needed, however, using qualitative methods and more
nuanced survey designs to determine precisely which
kinds of equity consideration decision makers think are
most important and why these considerations do not ap-
pear to be given much weight in decision making.
The next question to ask is: so what? Does it matter if
there is a mismatch between what health policy makers
say and do? It could be argued that the mismatch does
not matter, and that cost-effectiveness should remain the
dominant criterion in health technology funding deci-
sions irrespective of what policy makers say about equity
criteria. We would argue that this mismatch does mat-
ter. We agree with Shmueli that the decisions made by
policy makers should, as far as possible, reflect their
stated values and objectives. We therefore agree that
equity considerations are not currently given appropriate
weight in health technology reimbursement decisions,
both in Israel and more generally across the world, and
that ways need to be found of giving them greater prior-
ity. Finally, we would go further than Shumeli in arguing
that one key way to facilitate this is to quantify equity
outcomes so that they receive the same attention in the
decision-making process as efficiency outcomes. There
are several analytical approaches now available that
quantify equity and efficiency considerations and assess
the potential trade-offs between them [3]. For example,
Norway [9] and the Netherlands [10] already use
methods for measuring and valuing severity of illness
alongside cost-effectiveness, based on the concept of
health shortfall or burden of illness, and we have re-
cently developed methods for measuring impacts on
inequality in lifetime health and analysing potential
trade-offs with cost-effectiveness, known as Distribu-
tional Cost-Effectiveness Analysis (DCEA) [11].
In summary: this pair of studies has a striking and im-
portant finding about a potential mismatch between
what health technology decision makers say and do
about equity. Despite methodological quibbles about the
study design, the finding does provide evidence
suggesting that equity considerations are not given
enough attention in practice. If this mismatch is con-
firmed in future research, this finding could prove influ-
ential in helping policymakers re-shape health
technology assessment processes to pay closer attention
to equity outcomes, not only in Israel but across the
world.
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